GlassScriptPhysician profile
David Scott Lahue
NPI 1861476327
$6,483.75
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,725 · 2020: $652 · 2021: $1,235 · 2022: $1,062 · 2023: $1,157 · 2024: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,347.89 | 2019-2024 | |
| Novo Nordisk INC | $909.99 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $568.37 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $406.13 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $400.31 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $389.58 | 2019-2024 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $367.38 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $214.08 | 2019-2024 | |
| Abbott Laboratories | $200.06 | 2019-2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $186.28 | 2019-2024 | Gardasil 9, Vaqta, Capvaxive |
| Amarin Pharma, INC. | $160.01 | 2019-2021 | |
| Astellas Pharma US INC | $159.62 | 2019-2024 | Myrbetriq, Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $136.34 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.55 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $89.41 | 2019-2024 | Repatha, Otezla |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lahue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.